Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its ...

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...

Patients in psychedelic trials often know if they’re taking the study drug or a placebo. But trial design changes could ...

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What ...

SAN DIEGO — AI adoption is still ticking up in pharma with 34% of companies leveraging the tech for specific functions, according to a recent GlobalData survey. Early drug development in particular ...

French drugmaker Sanofi has been playing the long game when it comes to the blockbuster Dupixent, and the results are starting to show. First approved for atopic dermatitis in 2017, the skin and ...